BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI) (NCT02805023)
Phase 1/2, Open Label & Double Blind Randomized Placebo-controlled Study to Assess the Feasibility of BGC101 (EnEPC) in the Treatment of Peripheral Arterial Disease (PAD) With Critical Limb Ischemia (CLI)
🩺 Plain-English Summary (8th-Grade Level)
Evaluate the feasibility of an autologous cell preparation composed of a mixture of cells enriched for endothelial progenitor cells (EnEPCs) and multipotent adult hematopoietic stem/progenitor cells (HSPC) (BGC101), in the treatment of patients suffering from peripheral arterial disease (PAD) with critical limb ischemia (CLI) who have not responded to optimal pharmacological treatment or control of risk factors and/or had a revascularization failure, and do not have the option of further revascularization treatment.
Who can join: Review the eligibility criteria below.
Location: University of San Francisco — San Francisco, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (5 Sites)
- University of San Francisco — San Francisco, California
- Yale University School of Medicine — New Haven, Connecticut
- Johns Hopkins Hospital — Baltimore, Maryland
- Rambam Health Care Campus — Haifa,
- Laniado Hospital — Netanya,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Limb-Threatening Ischemia
- Esprit BTK Post-Approval Study — Scottsdale, Arizona
- Chronic Limb-Threatening Ischemia Treated With Intravascular Lithotripsy Observational Study — Eisenstadt,
- Peripheral Bypass Trial for Completion Control — San Francisco, California
- Bioresorbable Sirolimus-Eluting Scaffold Treatment for Below the Knee Disease — New York, New York
Explore by condition: All Chronic Limb-Threatening Ischemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.